Abstract:The majority (84%) of the 50 most-sold pharmaceutical products in the US and European markets are given orally. The dominating role of this route in drug therapy is a consequence of it being safe, efficient and easily accessible with minimal discomfort to the patient in comparison with other routes of drug administration. A successful drug discovery and development of oral pharmaceutical products require an in-depth understanding of multiple biochemical and physiological processes that determine the dissolution rate, intestinal permeability, gastrointestinal transit, first-pass extraction and systemic exposure-time profiles of drugs. It is crucial to realize that these basic biopharmaceutic and pharmacokinetic properties are crucial to focus on to allow successful drug development. Identification of the rate-limiting step(s) in order to overcome these barriers and understanding of the sources of variability are important in the selection of suitable candidate molecules in drug development. Several reports based on in vitro investigations in various cell models have suggested that carrier-mediated intestinal efflux may be a major reason for incomplete absorption and variable bioavailability of drugs, as well being a site for drug-drug and specific food-drug interactions. However, many drugs which were initially suggested to undergo significant efflux in vitro were later shown to be completely absorbed in vivo. This apparent discrepancy between in vitro and in vivo results may be due to several factors that will be discussed in this review. Novel data on solubility and dissolution in human gastrointestinal derived fluids will be reviewed. The effect of food intake on solubility and dissolution rate of a range of drugs including felodipine, danazol, griseofulvin, cyclosporine, probucol and ubiquinone in simulated and real intestinal fluids is discussed. The biopharmaceutic and physicochemical data discussed here can potentially be used as a benchmark set for validation of new experimental techniques or in silico models in future. Factors such as structural diversity, commercial availability, price and a suitable analytical technique for quantification were considered in the selection of a specific drug set. Using the compiled data set lipophilicity as determined by reverse phase HPLC and permeability across Caco-2 cell monolayers were determined; means to overcome the experimental difficulties due to the diversity of the data are also discussed.

Drug transport and transport-metabolism interplay in the human and rat intestine

Absorption Barriers in the Rat Intestinal Mucosa: 2. Application of Physiologically Based Mathematical Models to Quantify Mechanisms of Drug Permeation and Metabolism

Drug Transport and Transport-Metabolism Interplay in the Human and Rat Intestine: Ex Vivo Studies with Precision-Cut Intestinal Slices

Is the Human Model RPTEC/TERT1 a Relevant Model for Assessing Renal Drug Efflux?

In Situ Perfusion Model in Rat Colon for Drug Absorption Studies: Comparison with Small Intestine and Caco-2 Cell Model.

Rifampicin Induces Gene, Protein, and Activity of P-Glycoprotein (ABCB1) in Human Precision-Cut Intestinal Slices

Human enteroid monolayers as a potential alternative for Ussing chamber and Caco-2 monolayers to study passive permeability and drug efflux

A Novel Model of P‐Glycoprotein Inhibitor Screening Using Human Small Intestinal Organoids

Human small intestinal and colonic tissue mounted in the Ussing chamber as a tool for characterizing the intestinal absorption of drugs

Novel In Vitro Models for Cell Differentiation and Drug Transport Studies of the Human Intestine

Evaluation of Intestinal Drug Absorption and Interaction Using Quadruple Single-Pass Intestinal Perfusion Coupled with Mass Spectrometry Imaging

Dose-Dependent Targeted Suppression of P-glycoprotein Expression and Function in Caco-2 Cells

3D organoids derived from the small intestine: An emerging tool for drug transport research

Assessment of P-glycoprotein function using canine intestinal organoid-derived epithelial interfaces

Regional Intestinal Drug Permeability and Effects of Permeation Enhancers in Rat

Intestinal P‐gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications

Measurement of Rhodamine 123 in Three-Dimensional Organoids: A Novel Model for P-Glycoprotein Inhibitor Screening.

Establishment of a P-glycoprotein Substrate Screening Model and Its Preliminary Application

Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans

Prediction of Human Absorption of Natural Compounds by the Non-Everted Rat Intestinal Sac Model

In Situ Single-Pass Perfused Rat Intestinal Model for Absorption and Metabolism